Placebo for Maridebart Cafraglutide

DRUG3 trials

Sponsors

Amgen Inc., Amgen

Conditions

Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweightChronic Weight ManagementObesityOverweight

Phase 1

Effect of Maridebart Cafraglutide on the Heart's Electrical Activity

Active, not recruitingNCT07229157

AmgenObesity, Overweight

Start: 2025-10-22End: 2026-08-26Updated: 2026-01-23

Phase 3

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-1)

Active, not recruitingCTIS2024-515524-36-00

Amgen Inc.Chronic Weight Management

Start: 2025-05-30Target: 1050Updated: 2025-09-18

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)

RecruitingCTIS2024-516652-18-00

Amgen Inc.Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweight

Start: 2025-10-10Target: 5564Updated: 2025-11-24